Doxycycline (Ophthalmic Use)
Key points at a glance
Section titled “Key points at a glance”1. What is Doxycycline?
Section titled “1. What is Doxycycline?”Definition and History
Section titled “Definition and History”Doxycycline is a semi-synthetic broad-spectrum antibiotic belonging to the tetracycline class. It was approved by the FDA in 1967.
The history of tetracyclines began during World War II. Chlortetracycline was discovered from Streptomyces aureofaciens, and oxytetracycline from Streptomyces rimosus. In 1953, Robert Woodward identified the common naphthacene skeleton (four aromatic rings) of both, giving rise to the name tetracycline. Through chemical modification, more stable and safer doxycycline was developed.
Pharmacokinetics
Section titled “Pharmacokinetics”- Absorption: Mainly in the duodenum. Oral bioavailability 95%. Time to peak plasma concentration 2–3 hours.
- Protein binding: 82–93%. Volume of distribution 0.7 L/kg.
- Metabolism: No significant metabolism. Excreted in active form.
- Excretion: Renal excretion 35–60%, biliary excretion 30–40%
- Elimination half-life: 12–25 hours
- Effect of food: Cations (Ca²⁺, Fe²⁺, Al³⁺) reduce serum concentration by about 20%; therefore, it is advisable to take the medication 1 hour before or 2 hours after a meal.
- Renal impairment: In chronic renal failure, biliary excretion increases compensatorily, so dose adjustment is not required.
Doxycycline and minocycline are more lipophilic than tetracycline and oxytetracycline, and are concentrated in ocular and eyelid tissues at lower doses2).
Cations such as calcium in meals and dairy products reduce absorption by about 20%; therefore, it is recommended to take the medication 1 hour before or 2 hours after a meal. Concurrent use with antacids (containing aluminum or calcium) should also be avoided.
2. Mechanism of Action
Section titled “2. Mechanism of Action”
Antibacterial Action
Section titled “Antibacterial Action”Tetracyclines bind to the 16S ribosomal RNA of the 30S ribosomal subunit, sterically inhibiting the interaction between aminoacyl-tRNA and the ribosomal A site1). This halts protein synthesis. They act bacteriostatically, so a functional immune system is required for eradication of infection.
They have a broad spectrum against Gram-positive bacteria, Gram-negative bacteria, Chlamydia, Mycoplasma, Rickettsia, and protozoa1).
Anti-inflammatory Action (Non-antibacterial Action)
Section titled “Anti-inflammatory Action (Non-antibacterial Action)”Independently of its antibacterial properties, doxycycline exhibits the following pleiotropic anti-inflammatory effects1).
- Mucous membrane pemphigoid inhibition: Suppresses matrix metalloproteinase activities such as collagenase, phospholipase A2, and MMP-91)
- Cytokine suppression: Reduces production of inflammatory mediators such as IL-1β and TNF-α in various tissues including the corneal epithelium1)
- Lipase production inhibition: Suppresses lipase production by ocular surface commensal bacteria, reducing breakdown products of meibomian gland lipids (e.g., free fatty acids)1)
Due to these properties, at doses of 50–100 mg, only anti-inflammatory effects are generally exerted on the ocular surface, and antibacterial effects are limited2).
Resistance Mechanisms
Section titled “Resistance Mechanisms”Microorganisms acquire resistance through acquisition via mobile genetic elements or selective mutations. Three mechanisms are known: efflux pumps, ribosomal protection, and enzymatic inactivation. Long-term administration at sub-antimicrobial doses (40 mg/day) is not considered to induce resistance1).
3. Ophthalmic Indications
Section titled “3. Ophthalmic Indications”Meibomian Gland Dysfunction (MGD)
Section titled “Meibomian Gland Dysfunction (MGD)”The efficacy of oral doxycycline for meibomian gland dysfunction has been investigated in several clinical trials1).
In a three-group RCT, 50 patients each were assigned to a high-dose group (200 mg twice daily), a low-dose group (20 mg twice daily), and a placebo group. Oral doxycycline provided slight improvement in subjective symptoms at 1 month, but the differences between groups were not statistically significant1).
Low-dose doxycycline (20 mg twice daily) shows comparable efficacy to high-dose (200 mg twice daily) and is associated with fewer side effects.
Ocular Rosacea
Section titled “Ocular Rosacea”For ocular symptoms associated with rosacea, extended-release doxycycline 40 mg once daily (Oracea®) is FDA-approved. In an RCT of 70 patients with anterior blepharitis and facial rosacea, doxycycline 40 mg once daily showed only slight improvement in subjective dry eye symptoms, but statistically significant improvements from baseline were observed in Schirmer test values and tear break-up time1).
Blepharitis
Section titled “Blepharitis”For chronic blepharitis and seborrheic meibomianitis, doxycycline reduces toxic byproducts by suppressing bacterial lipase production, thereby improving symptoms1).
Recurrent Corneal Erosion
Section titled “Recurrent Corneal Erosion”A protocol of oral doxycycline 50 mg twice daily for 2 months combined with 1% methylprednisolone eye drops three times daily (for 2–3 weeks) has been reported. It is thought to promote basement membrane repair by inhibiting mucosal pemphigoid.
Corneal Thinning and Perforation Risk
Section titled “Corneal Thinning and Perforation Risk”Oral doxycycline may counteract corneal thinning by inhibiting mucosal pemphigoid, but data on its use in infectious keratitis are limited3).
Generally, 50–100 mg is taken once or twice daily for several weeks to several months. Low doses (20 mg twice daily) may provide equivalent efficacy with fewer side effects. The duration of effect after discontinuation is not well established, so the treatment period should be determined in consultation with the physician.
4. Side Effects and Drug Interactions
Section titled “4. Side Effects and Drug Interactions”Main Side Effects
Section titled “Main Side Effects”- Gastrointestinal symptoms: Nausea, vomiting, diarrhea, epigastric irritation. Risk of esophagitis (remain upright for 30 minutes after taking).
- Photosensitivity: Skin reactions upon sun exposure. Adequate sun protection is necessary.
- Tooth discoloration: Permanent discoloration in children under 8 years (contraindicated).
- Bone growth inhibition: Effects on skeletal growth in children1).
- Intracranial hypertension: Rare serious side effect.
- Oropharyngeal and vaginal candidiasis: with long-term administration
- Hepatotoxicity: rare
- Gastrointestinal: Clostridium difficile-associated diarrhea
Contraindications
Section titled “Contraindications”- History of hypersensitivity to tetracyclines
- Pregnant and breastfeeding women
- Children under 8 years of age
Major drug interactions
Section titled “Major drug interactions”- Antacids (containing Fe²⁺, Al³⁺, Ca²⁺, bismuth subsalicylate): absorption inhibition. Separate administration by several hours.
- CYP3A4 inducers (barbiturates, antiepileptics): enhance hepatic metabolism of doxycycline
- Anticoagulants: may decrease plasma prothrombin activity and enhance anticoagulant effect
- Topical retinoids: increased risk of pseudotumor cerebri
- Oral contraceptives: possible decreased absorption of OCPs due to reduction of intestinal flora
- Methotrexate: Increased blood concentration due to competitive displacement from binding sites
5. Pathophysiology: Detailed Mechanism of Mucous Membrane Pemphigoid Inhibition
Section titled “5. Pathophysiology: Detailed Mechanism of Mucous Membrane Pemphigoid Inhibition”Mucous Membrane Pemphigoid Inhibition and Corneal Protection
Section titled “Mucous Membrane Pemphigoid Inhibition and Corneal Protection”Doxycycline directly inhibits mucous membrane pemphigoid-9 and suppresses MAPK signal activation, reducing inflammatory cytokine expression in corneal epithelium, as shown in experimental dry eye models1).
Oral doxycycline, topical N-acetylcysteine, and medroxyprogesterone all have mucous membrane pemphigoid inhibitory effects and have been considered as treatment options for persistent epithelial defects and stromal thinning. However, evaluation of in vivo efficacy is difficult, especially in a structured double-blind setting.
Effects on Meibomian Gland Lipid Metabolism
Section titled “Effects on Meibomian Gland Lipid Metabolism”Tetracyclines reduce bacterial lipolytic exoenzymes and suppress lipase production, thereby decreasing breakdown products of meibomian gland lipids1). This improves clinical parameters of evaporative dry eye.
Notably, in vitro human meibomian gland cell culture studies showed that azithromycin significantly increased intracellular accumulation of cholesterol, phospholipids, and lysosomes, while doxycycline, minocycline, and tetracycline did not show such effects1).
6. Latest Research and Future Perspectives
Section titled “6. Latest Research and Future Perspectives”Comparison with Azithromycin
Section titled “Comparison with Azithromycin”In a crossover RCT enrolling 115 patients, doxycycline (30 days: 100 mg twice daily for 7 days, then 100 mg/day for 21 days) was compared with azithromycin (5 days: 500 mg on day 1, then 250 mg/day for 4 days). Both antibiotics were effective and safe for persistent meibomian gland dysfunction over 9 months, but azithromycin required lower dosage and shorter duration1).
A systematic review and meta-analysis suggested that oral azithromycin may be more effective than oral doxycycline in improving signs of meibomian gland dysfunction. Azithromycin also had fewer gastrointestinal side effects1).
However, it should be noted that azithromycin carries risks of serious side effects such as cardiac arrhythmia, pancreatitis, and dizziness1). The optimal antibiotic treatment for meibomian gland dysfunction has not yet been established1).
Challenges regarding the sustainability of treatment effects
Section titled “Challenges regarding the sustainability of treatment effects”Two reviews concluded that antimicrobial therapy for ocular surface diseases associated with posterior blepharitis or meibomian gland dysfunction provides short-term improvement during the treatment period, but there is insufficient evidence for sustained improvement after discontinuation of treatment1). Considering the unclear long-term benefits, gastrointestinal side effects, and potential systemic issues such as malignancy, combination with in-office procedures (e.g., warm compresses, IPL) is recommended.
7. References
Section titled “7. References”- Jones L, Downie LE, Korb D, et al. TFOS DEWS III Management and Therapy Report. Am J Ophthalmol. 2025;279:301-399.
- Sabeti S, Kheirkhah A, Yin J, Dana R. Management of Meibomian Gland Dysfunction: A Review. Surv Ophthalmol. 2020;65:205-217.
- Austin A, Lietman T, Rose-Nussbaumer J. Update on the Management of Infectious Keratitis. Ophthalmology. 2017;124:1678-1689.